<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiol Res</journal-id><journal-id journal-id-type="iso-abbrev">Cardiol Res</journal-id><journal-id journal-id-type="publisher-id">Elmer Press</journal-id><journal-title-group><journal-title>Cardiology Research</journal-title></journal-title-group><issn pub-type="ppub">1923-2829</issn><issn pub-type="epub">1923-2837</issn><publisher><publisher-name>Elmer Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28197227</article-id><article-id pub-id-type="pmc">5295555</article-id><article-id pub-id-type="doi">10.14740/cr375w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Intracoronary Stem Cell Injection on Markers of Leukocyte Activation in Acute Myocardial Infarction</article-title><alt-title alt-title-type="short">Leukocyte Markers During AMI</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Helseth</surname><given-names>Ragnhild</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ab">b</xref><xref ref-type="corresp" rid="CORd">d</xref></contrib><contrib contrib-type="author"><name><surname>Opstad</surname><given-names>Trine</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ab">b</xref></contrib><contrib contrib-type="author"><name><surname>Solheim</surname><given-names>Svein</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib><contrib contrib-type="author"><name><surname>Lunde</surname><given-names>Ketil</given-names></name><xref ref-type="aff" rid="Ac">c</xref></contrib><contrib contrib-type="author"><name><surname>Arnesen</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ab">b</xref></contrib><contrib contrib-type="author"><name><surname>Seljeflot</surname><given-names>Ingebjorg</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ab">b</xref></contrib></contrib-group><aff id="Aa"><label>a</label>Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway</aff><aff id="Ab"><label>b</label>Faculty of Medicine, University of Oslo, Oslo, Norway</aff><aff id="Ac"><label>c</label>Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway</aff><author-notes><corresp id="CORd"><label>d</label>Corresponding Author: Ragnhild Helseth, Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ulleval, PO Box 4956 Nydalen, 0424 Oslo, Norway. Email: <email>ragnhild.helseth@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>09</day><month>2</month><year>2015</year></pub-date><volume>6</volume><issue>1</issue><fpage>209</fpage><lpage>215</lpage><history><date date-type="accepted"><day>24</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>Copyright 2015, Helseth et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="a1"><title>Background</title><p>Beneficial effects of stem cell treatment during acute myocardial infarction (AMI) have been suggested, but the effects on inflammation are controversial. The neutrophil cell markers pentraxin 3 (PTX3) and myeloperoxidase (MPO) are both reported to be elevated during AMI. We studied the effects of stem cell treatment in ST-elevation myocardial infarction (STEMI) on PTX3 and MPO levels.</p></sec><sec id="a2"><title>Methods</title><p>Subjects with STEMI undergoing percutaneous coronary intervention (PCI) were randomized to intracoronary injection of bone marrow cells (mBMCs) (n = 50) or controls (n = 50). Blood samples were drawn 1 day before mBMC injection (baseline), after 1 day, 3 days, 2 - 3 weeks and 3 months. Enzyme-linked immunosorbent assay (ELISA) and RT-PCR were used for biochemical analysis. Myocardial necrosis was quantified by single photon emission computed tomography (SPECT) and creatine kinase MB (CKMB) levels.</p></sec><sec id="a3"><title>Results</title><p>PTX3 and MPO levels did not differ between the groups at any time points. Within the mBMC group, overall changes in both variables were observed (P &#x0003c; 0.01), with decreased levels from baseline throughout. Within the control group, similar patterns were observed. The relative reduction of PTX3 from baseline to day 1 was significantly less pronounced in the mBMC group compared to controls (P = 0.002), whereas no differences in relative changes from baseline were observed for MPO. Plasma and gene expression levels of PTX3 in leukocytes correlated significantly at all time points (r = 0.379 - 0.448, P &#x0003c; 0.01, all). MPO was significantly correlated to baseline left ventricular ejection fraction (LVEF) (r = -0.229, P = 0.025) and peak CKMB (r = 0.200, P = 0.05).</p></sec><sec id="a4"><title>Conclusions</title><p>Stem cell treatment had limited effect on plasma levels of PTX3 and MPO. The initially high PTX3 and MPO levels, the genetic regulation of PTX3 and the association between MPO and myocardial injury support the importance of neutrophil cell activation in STEMI.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Bone marrow stem cells</kwd><kwd>Stem cell treatment</kwd><kwd>Acute myocardial infarction</kwd><kwd>Neutrophil markers</kwd><kwd>Pentraxin 3</kwd><kwd>Myeloperoxidase</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Despite standardized acute medical care and early percutaneous coronary intervention (PCI), loss of viable myocardium is still a major clinical issue in acute myocardial infarction (AMI). Although a certain myocardial regeneration is exacerbated in AMI [<xref rid="R01" ref-type="bibr">1-3</xref>], this mitotic activity is obviously not adequate to prevent a net loss of viable cardiomyocytes. Administration of bone marrow-derived stem cells (mBMCs) in human subjects with AMI has been suggested to moderately improve left ventricular ejection fraction (LVEF) and reduce infarct size, although conflicting results exist [<xref rid="R04" ref-type="bibr">4</xref>]. The mechanism behind the proposed beneficial effect of mBMCs is probably multifactorial, involving paracrine effects through secretion of cytokines and growth factors on cytoprotection, neovascularization and cardiac repair [<xref rid="R05" ref-type="bibr">5</xref>, <xref rid="R06" ref-type="bibr">6</xref>].</p><p>The number of circulating neutrophil granulocytes has been reported to increase during AMI, and this increase is associated with infarct size, left ventricular function and mortality [<xref rid="R07" ref-type="bibr">7</xref>, <xref rid="R08" ref-type="bibr">8</xref>]. Neutrophil granulocytes secrete a varietey of mediators which may link neutrophil cell activation to atherosclerosis, plaque vulnerability and cardiac remodeling [<xref rid="R09" ref-type="bibr">9-11</xref>].</p><p>Pentraxin 3 (PTX3) is a member of the pentraxin family and is produced by a variety of cells in response to inflammatory stimuli [<xref rid="R12" ref-type="bibr">12</xref>]. Levels of PTX3 are reported to be elevated in the early phase of AMI [<xref rid="R13" ref-type="bibr">13-15</xref>], and an immediate source of secretion is suggested to be the granules of circulating neutrophils [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R16" ref-type="bibr">16</xref>]. By displaying both pro- and antiinflammatory effects [<xref rid="R12" ref-type="bibr">12</xref>], the exact role of PTX3 in atherothrombosis and subsequent mycardial remodeling is controversial. Its circulating levels during AMI have, nevertheless, been shown to be associated with the risk of new coronary events and mortality [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. A recent study in mice with subcutaneous transplantation of mesenchymal stem cells in AMI reported improved left ventricular function and increased genetic expression of PTX3, suggesting that part of the cardioprotective effect of stem cell therapy was mediated by PTX3 [<xref rid="R19" ref-type="bibr">19</xref>].</p><p>The hemeprotein myeloperoxidase (MPO) is secreted from the granules of activated neutrophils, monocytes and macrophages. MPO participates in the atherosclerotic process through stimulated LDL oxidation, endothelial dysfunction and plaque instability [<xref rid="R20" ref-type="bibr">20</xref>], and has also been associated with adverse ventricular remodeling [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R21" ref-type="bibr">21</xref>]. High levels of MPO have been reported in the acute phase of AMI [<xref rid="R22" ref-type="bibr">22</xref>] and also to be an independent risk factor for development of cardiovascular disease (CVD) [<xref rid="R20" ref-type="bibr">20</xref>]. Administration of stem cells derived from bone marrow, adipose tissue and umbilical cord has in different rat models been reported to reduce MPO activity [<xref rid="R23" ref-type="bibr">23-26</xref>].</p><p>The present study is a substudy of the autologeous stem-cell transplantation in acute myocardial infarction (ASTAMI) trial [<xref rid="R27" ref-type="bibr">27</xref>] investigating the effect of intracoronary administration of mBMCs on PTX3 and MPO levels and the relation between these neutrophil cell markers and myocardial injury. We hypothesized that mBMCs would reduce levels of neutrophil cell markers and that levels of the biomarkers would be associated with myocardial injury.</p></sec><sec sec-type="materials | methods" id="s2"><title>Material and Methods</title><sec id="s2a"><title>Subjects and study design</title><p>Data presented in this study are based on blood samples obtained from participants in the ASTAMI trial. Details of the ASTAMI study design have been given previously [<xref rid="R28" ref-type="bibr">28</xref>]. Briefly, subjects within the age 40 - 75 years (n = 100) with anterior wall ST-elevation myocardial infarction (STEMI) were randomized to intracoronary injection of autologeous mBMC or to a control group without injection. Both groups underwent primary PCI with stent implantation of the left anterior descending artery (LAD). Main exclusion criteria were previous Q-wave infarction, cardiogenic shock or serious comorbidity interfering with protocol compliance.</p><p>The ASTAMI trial was approved by the Regional Committee for Medical Research Ethics and all included subjects gave written informed consent for study participation. The study is registered at ClinicalTrials.gov, NCT 00199823.</p></sec><sec id="s2b"><title>Laboratory methods</title><sec id="s2b1"><title>Blood sampling</title><p>Blood samples were obtained by standard venipuncture after an overnight fast, before morning medication between 8 am and 9 am. Blood samples were taken at baseline (4 - 5 days after the AMI and 1 day before stem cell treatment) and then after day 1, day 3, 2 - 3 weeks and 3 months.</p></sec><sec id="s2b2"><title>Enzyme immunoassays</title><p>PTX3 and MPO levels were determined by commercially available enzyme-linked immunosorbent assays (ELISA) in EDTA plasma (R&#x00026;D Systems, Abingdon, Oxon, UK and Mercodia AB, Uppsala, Sweden, respectively), prepared within 1 h by 10 min centrifugation at 4 &#x000b0;C at 2,500 &#x000d7; g. Plasma samples were stored at -80 &#x000b0;C prior to analyses. Samples from all time points were measured in the same run in order to avoid bias due to assay variability. The inter-assay coefficients of variation for PTX3 and MPO were 8.5% and 8.9%, respectively.</p></sec><sec id="s2b3"><title>Gene expression analysis</title><p>PAXgene blood RNA tubes (Preanalytix Qiagen GmBH, Germany) were collected in a randomly selected subset of patients at all time points (n = 48). RNA isolation was performed by a PAXgene<sup>&#x000ae;</sup> Blood RNA Kit (PreAnalytix, Qiagen) with an additional cleaning step (RNeasy<sup>&#x000ae;</sup> MinElute<sup>&#x000ae;</sup> Cleanup Kit, Qiagen). Total RNA was reversely transcribed into complementary DNA (cDNA) by use of qScript cDNA SuperMix (Quanta Biosciences, Inc., Gaithersburg, USA). PTX3 and MPO mRNA levels were then determined by RT-PCR by the Viia<sup>TM</sup> 7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), normalized to &#x003b2;2-microglobulin (HS99999907_m1, Applied Biosystems) and calculated as relative quantification using the previously described &#x00394;&#x00394;Ct method [<xref rid="R29" ref-type="bibr">29</xref>].</p></sec><sec id="s2b4"><title>Left ventricular function and infarct size assessment</title><p>LVEF and size of infarcted LAD perfusion area (%) were obtained by electrocardiogram-gated single photon emission computed tomography (SPECT) (GE Medical Systems) with 4D-MSPECT software at baseline (4.0 &#x000b1; 1.4 days after the acute event). Myocardial necrosis was additionally quantified by peak levels of creatine kinase MB (CKMB).</p></sec></sec><sec id="s2c"><title>Statistical analysis</title><p>As levels of both PTX3 and MPO were skewly distributed, non-parametric statistics were used throughout. Descriptive data are given as mean (standard deviation (SD)), proportions (numbers) and medians (25, 75 percentiles) as appropriate. Intergroup differences were assessed by two-sample <italic>t</italic>-test, Mann-Whitney test for two independent samples or Chi-square test as appropriate. Mann-Whitney test for two independent samples was used to analyze differences in relative change from baseline between the randomized groups. Overall intragroup change was assessed by Friedsman test, followed by Wilcoxon signed-rank test. Correlation analyses were performed using the Spearman rho. P-value of &#x0003c; 0.05 was considered significant. Data analyses were performed using SPSS Statistics, Version 21 and 22.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Study population</title><p>In all, 100 patients were randomized to either intracoronary injection of mBMCs (n = 50) or to the control group (n = 50) (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Subject characteristics did not differ significantly between the groups at inclusion (<xref ref-type="table" rid="T1">Table 1</xref>), and LVEF did not differ significantly between the groups at 6 months [<xref rid="R28" ref-type="bibr">28</xref>].</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram. </p></caption><graphic xlink:href="cr-06-209-g001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of the Study Population According to the Randomized Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">mBMC group (n = 50)</th><th align="left" rowspan="1" colspan="1">Control group (n = 50)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">58.1 (8.5)</td><td align="left" valign="top" rowspan="1" colspan="1">56.7 (9.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (n of males)</td><td align="left" valign="top" rowspan="1" colspan="1">42</td><td align="left" valign="top" rowspan="1" colspan="1">42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension (n)</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes (n)</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smokers (n)</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">26.3 (3.9)</td><td align="left" valign="top" rowspan="1" colspan="1">27.1 (3.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">4.4 (3.7 - 5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">4.5 (3.8 - 4.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">2.9 (2.3 - 3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2.9 (2.4 - 3.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL cholesterol (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.8 - 1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (0.9 - 1.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (1.0 - 1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (1.1 - 1.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LVEF (%)</td><td align="left" valign="top" rowspan="1" colspan="1">43 (35, 48)</td><td align="left" valign="top" rowspan="1" colspan="1">44 (34 - 49)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peak CKMB (ng/L)</td><td align="left" valign="top" rowspan="1" colspan="1">400 (220.5 - 447.0)</td><td align="left" valign="top" rowspan="1" colspan="1">357 (205.0 - 423.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline WBC count (10<sup>9</sup>/L)</td><td align="left" valign="top" rowspan="1" colspan="1">8.1 (6.8 - 9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">8.4 (7.1 - 8.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline neutrophile count (10<sup>9</sup>/L)</td><td align="left" valign="top" rowspan="1" colspan="1">4.6 (3.8 - 5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">4.8 (4.1 - 5.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication at discharge</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aspirin (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clopidogrel (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACE-I/ATII antagonist (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">98</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beta blocker (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Statin (%)</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diuretics (%)</td><td align="left" valign="top" rowspan="1" colspan="1">42</td><td align="left" valign="top" rowspan="1" colspan="1">32</td></tr></tbody></table><table-wrap-foot><fn><p>Values are given as mean (SD), proportions (n), medians (25, 75 percentiles) or percent (%). ACE-I: angiotensin-converting-enzyme inhibitor; ATII antagonist: antiotensin II antagonist; WBC: white blood cell.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>The effect of intracoronary injection of mBMC</title><p>Plasma levels of PTX3 and MPO did not differ between the mBMC group and the control group at any time point (<xref ref-type="table" rid="T2">Table 2</xref>). Relative reduction of PTX3 from baseline to day 1 was less pronounced in the mBMC group compared to the control group (P = 0.002) (<xref ref-type="table" rid="T2">Table 2</xref>), whereas no between group differences in relative changes from baseline were observed for MPO.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Plasma Levels of PTX3 and MPO According to the Randomized Groups at Baseline and Follow-Up </title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Baseline</th><th align="left" rowspan="1" colspan="1">Day 1</th><th align="left" rowspan="1" colspan="1">Day 3</th><th align="left" rowspan="1" colspan="1">2 - 3 weeks</th><th align="left" rowspan="1" colspan="1">3 months</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">PTX3 (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;mBMC group</td><td align="left" valign="top" rowspan="1" colspan="1">0.92 (0.67 - 1.38)</td><td align="left" valign="top" rowspan="1" colspan="1">0.91<sup>&#x000a7;</sup> (0.68 - 1.41)</td><td align="left" valign="top" rowspan="1" colspan="1">0.84* (0.50 - 1.28)</td><td align="left" valign="top" rowspan="1" colspan="1">0.74* (0.45 - 1.31)</td><td align="left" valign="top" rowspan="1" colspan="1">0.62* (0.46 - 1.19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Control group</td><td align="left" valign="top" rowspan="1" colspan="1">1.18 (0.71 - 1.33)</td><td align="left" valign="top" rowspan="1" colspan="1">0.76* (0.49 - 1.17)</td><td align="left" valign="top" rowspan="1" colspan="1">0.73* (0.47 - 1.06)</td><td align="left" valign="top" rowspan="1" colspan="1">0.68* (0.42 - 1.10)</td><td align="left" valign="top" rowspan="1" colspan="1">0.68* (0.35 - 1.06)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MPO (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;mBMC group</td><td align="left" valign="top" rowspan="1" colspan="1">80 (60 - 120)</td><td align="left" valign="top" rowspan="1" colspan="1">82* (60 - 106)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (57 - 106)</td><td align="left" valign="top" rowspan="1" colspan="1">71* (54 - 98)</td><td align="left" valign="top" rowspan="1" colspan="1">69* (49 - 92)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Control group</td><td align="left" valign="top" rowspan="1" colspan="1">79 (59 - 115)</td><td align="left" valign="top" rowspan="1" colspan="1">76 (54 - 101)</td><td align="left" valign="top" rowspan="1" colspan="1">75* (61 - 92)</td><td align="left" valign="top" rowspan="1" colspan="1">73* (53 - 83)</td><td align="left" valign="top" rowspan="1" colspan="1">64* (48 - 88)</td></tr></tbody></table><table-wrap-foot><fn><p>Values are given as median (25, 75 pencentiles).</p><p><sup>&#x000a7;</sup>Difference in relative change from baseline (P &#x0003c; 0.05) between the groups. *Change from baseline (P &#x0003c; 0.05) within the respective treatment groups.</p></fn></table-wrap-foot></table-wrap><p>Within the mBMC group, an overall change in PTX3 and MPO was observed (P &#x0003c; 0.01 for both), with decreasing levels from baseline to day 3 and further to all time points for PTX3 (P &#x0003c; 0.05 for all) and decreased levels from baseline to day 1, 2 - 3 weeks and 3 months for MPO (P &#x0003c; 0.05 for all). Within the control group, an overall change in PTX3 and MPO was also observed (P &#x0003c; 0.01 for both) with similar patterns as observed within the mBMC group (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec id="s3c"><title>Gene expression in leukocytes</title><p>Intracoronary injection of mBMCs did not influence gene expression of PTX3 and MPO in circulating leukocytes (n = 48), except from a greater relative reduction in MPO gene expression at 3 months in the mBMC group (P &#x0003c; 0.05, data not shown). In the total subpopulation, the gene expression of PTX3 and MPO decreased from baseline throughout the study period within the range of 16-39% and 16-48%, respectively (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Gene expression of PTX3 correlated significantly to circulating PTX3 levels at all corresponding time points from baseline to 3 months (r = 0.379 - 0.448, P &#x0003c; 0.01 for all). Baseline correlation is shown in <xref ref-type="fig" rid="F3">Figure 3</xref>. No such correlation was observed for MPO.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Gene expression of PTX3 (panel a) and MPO (panel b) at follow-up relative to baseline in the randomly selected subset (n = 48) of the total population. </p></caption><graphic xlink:href="cr-06-209-g002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Correlation between plasma levels and gene expression levels of PTX3 in circulating leukocytes at baseline. </p></caption><graphic xlink:href="cr-06-209-g003"/></fig></sec><sec id="s3d"><title>Correlations between biomarkers and LVEF, myocardial necrosis and leukocyte count</title><p>Baseline PTX3 levels did not correlate to baseline LVEF or infarct size measured by neither SPECT nor peak CKMB. Baseline MPO levels correlated inversely to baseline LVEF (P = 0.025) and positively to peak CKMB (P = 0.05) (<xref ref-type="table" rid="T3">Table 3</xref>). Baseline neutrophile count correlated to both plasma PTX3 and plasma MPO at day 1 (r = 0.271, P = 0.012 and r = 0.275, P = 0.01, respectively).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Correlations Between Biomarkers, LVEF and Myocardial Necrosis </title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1"/><th colspan="2" align="center" rowspan="1">Baseline PTX3<hr/></th><th colspan="2" align="center" rowspan="1">Baseline MPO<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">r</th><th align="left" rowspan="1" colspan="1">P</th><th align="left" rowspan="1" colspan="1">r</th><th align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline LVEF<sup>&#x000a7;</sup></td><td align="left" valign="top" rowspan="1" colspan="1">-0.110</td><td align="left" valign="top" rowspan="1" colspan="1">0.290</td><td align="left" valign="top" rowspan="1" colspan="1">-0.229</td><td align="left" valign="top" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Infarct size*</td><td align="left" valign="top" rowspan="1" colspan="1">-0.014</td><td align="left" valign="top" rowspan="1" colspan="1">0.892</td><td align="left" valign="top" rowspan="1" colspan="1">0.101</td><td align="left" valign="top" rowspan="1" colspan="1">0.323</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Peak CKMB</td><td align="left" valign="top" rowspan="1" colspan="1">0.037</td><td align="left" valign="top" rowspan="1" colspan="1">0.720</td><td align="left" valign="top" rowspan="1" colspan="1">0.200</td><td align="left" valign="top" rowspan="1" colspan="1">0.05</td></tr></tbody></table><table-wrap-foot><fn><p><sup>&#x000a7;</sup>SPECT. *Proportion of LAD perfusion area.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>In this substudy of the ASTAMI trial, administration of autologous mBMCs after STEMI had limited effect on PTX3 and MPO levels. However, both leukocyte markers were highest early after the STEMI, indicating transient leukocyte activation. Plasma levels of PTX3 seemed to reflect PTX3 gene expression in leukocytes, and plasma levels of MPO were significantly related to LVEF and myocardial necrosis.</p><p>As previously reported from the ASTAMI study and in line with other studies, no improvement of LVEF 6 months after mBMC treatment could be demonstrated [<xref rid="R28" ref-type="bibr">28-32</xref>]. In the present study, administration of mBMCs did not affect plasma levels of PTX3 and MPO beyond a smaller relative reduction of PTX3 from baseline to day 1. While mBMC treatment might not influence LVEF, it might stimulate early prolongation of neutrophil activation, the significance of which remains to be explored. To the best of our knowledge, this is the first report on leukocyte activation by mBMCs in humans.</p><p>Elevated PTX3 levels have been reported in the acute phase of AMI, peaking around less than 8 h [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R15" ref-type="bibr">15</xref>] and normalized levels have been reported 48 h after the acute event [<xref rid="R14" ref-type="bibr">14</xref>]. MPO levels have been reported to be elevated until 4 h after the acute event with a subsequent decline to 12 h and then a rise after 24 h [<xref rid="R22" ref-type="bibr">22</xref>]. A substantial amount of neutrophils has furthermore been reported to be completely depleted of MPO within the first 24 h after symptom onset [<xref rid="R33" ref-type="bibr">33</xref>]. Our analyses of PTX3 and MPO from a median of 4 - 5 days after the acute event are probably in a declining phase. Interestingly, we still observed a significant decrease in both markers throughout the study period, indicating prolonged leukocyte activation in the subacute phase of STEMI.</p><p>Though mainly not influenced by mBMC, gene expression of PTX3 and MPO in circulating leukocytes decreased throughout the study period suggesting elevated gene expression in the subacute phase of AMI. We observed, however, a strong correlation between gene expression of PTX3 and plasma levels of PTX3 at all corresponding time points. These observations indicate that the PTX3 measured in the circulation to a major degree originated from a rapid secretion from circulating leukocytes, a finding which also previously has been discussed [<xref rid="R14" ref-type="bibr">14</xref>]. The absence of a similar correlation for MPO makes it tempting to speculate that circulating MPO levels originated from other cellular sources than circulating leukocytes, for instance from stationary leukocytes embedded in the myocardium [<xref rid="R34" ref-type="bibr">34</xref>] or within the culprit lesion [<xref rid="R35" ref-type="bibr">35</xref>]. The significant correlation between both plasma PTX3 and MPO and neutrophil cell count, however, indicates that some release from neutrophil storage pools might be present, in accordance with existing literature [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R33" ref-type="bibr">33</xref>].</p><p>In line with some other reports [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R15" ref-type="bibr">15</xref>], though not all [<xref rid="R36" ref-type="bibr">36</xref>], we could not observe any correlation between PTX3 levels and LVEF or indices of myocardial injury. Interestingly, PTX3 levels have been reported elevated in heart failure with normal ejection fraction and diastolic dysfunction [<xref rid="R37" ref-type="bibr">37</xref>]. Baseline MPO levels, however, correlated inversely to baseline LVEF and positively to peak CKMB. In line with our observations, inverse correlation between peak MPO and functional recovery of infarcted myocardial regions [<xref rid="R38" ref-type="bibr">38</xref>] and preservation of left ventricular function after AMI in MPO-/- mice [<xref rid="R11" ref-type="bibr">11</xref>] has been reported. The pathophysiological mechanism behind the possible role of MPO as an actor in adverse ventricular remodeling and heart failure development after AMI has been suggested to be decreased inactivation of plasminogen activator inhibitor-1 (PAI-1) by MPO-generated oxidants with resultant decreased plasmin activity [<xref rid="R11" ref-type="bibr">11</xref>].</p><sec id="s4a"><title>Limitations</title><p>Assessment of PTX3 and MPO in relation to LVEF was not predefined endpoints in the ASTAMI trial, hence power calculation as to significant effect of mBMC on these spesific markers has not been performed. The median number of bone marrow cells injected (68 &#x000d7; 10<sup>6</sup>) could be discussed, as could also the timing of the intervention procedure [<xref rid="R28" ref-type="bibr">28</xref>].</p></sec><sec id="s4b"><title>Conclusions</title><p>Administration of mBMCs after STEMI had limited effect on plasma levels of PTX3 and MPO. The initially high PTX3 and MPO levels, the genetic regulation of PTX3 in circulating leukocytes and the correlation between MPO and myocardial injury support the importance of neutrophil cell activation in STEMI.</p></sec></sec></body><back><ack><p>The work was supported by Stein Erik Hagen Foundation for Clinical Heart Research, Oslo, Norway.</p></ack><sec id="s5"><title>Disclosures</title><p>None.</p></sec><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><name><surname>Beltrami</surname><given-names>AP</given-names></name><name><surname>Urbanek</surname><given-names>K</given-names></name><name><surname>Kajstura</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>SM</given-names></name><name><surname>Finato</surname><given-names>N</given-names></name><name><surname>Bussani</surname><given-names>R</given-names></name><name><surname>Nadal-Ginard</surname><given-names>B</given-names></name><etal>et al</etal><article-title>Evidence that human cardiac myocytes divide after myocardial infarction</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><issue>23</issue><fpage>1750</fpage><lpage>1757</lpage><pub-id pub-id-type="doi">10.1056/NEJM200106073442303</pub-id><pub-id pub-id-type="pmid">11396441</pub-id></element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><name><surname>Bergmann</surname><given-names>O</given-names></name><name><surname>Bhardwaj</surname><given-names>RD</given-names></name><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>Zdunek</surname><given-names>S</given-names></name><name><surname>Barnabe-Heider</surname><given-names>F</given-names></name><name><surname>Walsh</surname><given-names>S</given-names></name><name><surname>Zupicich</surname><given-names>J</given-names></name><etal>et al</etal><article-title>Evidence for cardiomyocyte renewal in humans</article-title><source>Science</source><year>2009</year><volume>324</volume><issue>5923</issue><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1126/science.1164680</pub-id><pub-id pub-id-type="pmid">19342590</pub-id></element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><name><surname>Mollova</surname><given-names>M</given-names></name><name><surname>Bersell</surname><given-names>K</given-names></name><name><surname>Walsh</surname><given-names>S</given-names></name><name><surname>Savla</surname><given-names>J</given-names></name><name><surname>Das</surname><given-names>LT</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Silberstein</surname><given-names>LE</given-names></name><etal>et al</etal><article-title>Cardiomyocyte proliferation contributes to heart growth in young humans</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><issue>4</issue><fpage>1446</fpage><lpage>1451</lpage><pub-id pub-id-type="doi">10.1073/pnas.1214608110</pub-id><pub-id pub-id-type="pmid">23302686</pub-id></element-citation></ref><ref id="R04"><label>4</label><element-citation publication-type="journal"><name><surname>Clifford</surname><given-names>DM</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><name><surname>Brunskill</surname><given-names>SJ</given-names></name><name><surname>Doree</surname><given-names>C</given-names></name><name><surname>Mathur</surname><given-names>A</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Martin-Rendon</surname><given-names>E</given-names></name><article-title>Stem cell treatment for acute myocardial infarction</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>2</volume><fpage>CD006536</fpage><pub-id pub-id-type="pmid">22336818</pub-id></element-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><name><surname>Bartunek</surname><given-names>J</given-names></name><name><surname>Vanderheyden</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Terzic</surname><given-names>A</given-names></name><article-title>Cells as biologics for cardiac repair in ischaemic heart failure</article-title><source>Heart</source><year>2010</year><volume>96</volume><issue>10</issue><fpage>792</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1136/hrt.2007.139394</pub-id><pub-id pub-id-type="pmid">20448133</pub-id></element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><name><surname>Gnecchi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Ni</surname><given-names>A</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name><article-title>Paracrine mechanisms in adult stem cell signaling and therapy</article-title><source>Circ Res</source><year>2008</year><volume>103</volume><issue>11</issue><fpage>1204</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.176826</pub-id><pub-id pub-id-type="pmid">19028920</pub-id></element-citation></ref><ref id="R07"><label>7</label><element-citation publication-type="journal"><name><surname>Chia</surname><given-names>S</given-names></name><name><surname>Nagurney</surname><given-names>JT</given-names></name><name><surname>Brown</surname><given-names>DF</given-names></name><name><surname>Raffel</surname><given-names>OC</given-names></name><name><surname>Bamberg</surname><given-names>F</given-names></name><name><surname>Senatore</surname><given-names>F</given-names></name><name><surname>Wackers</surname><given-names>FJ</given-names></name><etal>et al</etal><article-title>Association of leukocyte and neutrophil counts with infarct size, left ventricular function and outcomes after percutaneous coronary intervention for ST-elevation myocardial infarction</article-title><source>Am J Cardiol</source><year>2009</year><volume>103</volume><issue>3</issue><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2008.09.085</pub-id><pub-id pub-id-type="pmid">19166685</pub-id></element-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><name><surname>Guasti</surname><given-names>L</given-names></name><name><surname>Dentali</surname><given-names>F</given-names></name><name><surname>Castiglioni</surname><given-names>L</given-names></name><name><surname>Maroni</surname><given-names>L</given-names></name><name><surname>Marino</surname><given-names>F</given-names></name><name><surname>Squizzato</surname><given-names>A</given-names></name><name><surname>Ageno</surname><given-names>W</given-names></name><etal>et al</etal><article-title>Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects</article-title><source>Thromb Haemost</source><year>2011</year><volume>106</volume><issue>4</issue><fpage>591</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1160/TH11-02-0096</pub-id><pub-id pub-id-type="pmid">21866299</pub-id></element-citation></ref><ref id="R09"><label>9</label><element-citation publication-type="journal"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Hazen</surname><given-names>SL</given-names></name><article-title>The role of myeloperoxidase in the pathogenesis of coronary artery disease</article-title><source>Jpn J Infect Dis</source><year>2004</year><volume>57</volume><issue>5</issue><fpage>S21</fpage><fpage>22</fpage><pub-id pub-id-type="pmid">15507760</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Koga</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Nakata</surname><given-names>T</given-names></name><name><surname>Takeno</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>N</given-names></name><name><surname>Koide</surname><given-names>Y</given-names></name><etal>et al</etal><article-title>Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound</article-title><source>JACC Cardiovasc Interv</source><year>2013</year><volume>6</volume><issue>9</issue><fpage>945</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2013.04.024</pub-id><pub-id pub-id-type="pmid">23954061</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Askari</surname><given-names>AT</given-names></name><name><surname>Brennan</surname><given-names>ML</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Drinko</surname><given-names>J</given-names></name><name><surname>Morehead</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>JD</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name><etal>et al</etal><article-title>Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction</article-title><source>J Exp Med</source><year>2003</year><volume>197</volume><issue>5</issue><fpage>615</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1084/jem.20021426</pub-id><pub-id pub-id-type="pmid">12615902</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Kunes</surname><given-names>P</given-names></name><name><surname>Holubcova</surname><given-names>Z</given-names></name><name><surname>Kolackova</surname><given-names>M</given-names></name><name><surname>Krejsek</surname><given-names>J</given-names></name><article-title>Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response</article-title><source>Mediators Inflamm</source><year>2012</year><volume>2012</volume><fpage>920517</fpage><pub-id pub-id-type="doi">10.1155/2012/920517</pub-id><pub-id pub-id-type="pmid">22577258</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Peri</surname><given-names>G</given-names></name><name><surname>Introna</surname><given-names>M</given-names></name><name><surname>Corradi</surname><given-names>D</given-names></name><name><surname>Iacuitti</surname><given-names>G</given-names></name><name><surname>Signorini</surname><given-names>S</given-names></name><name><surname>Avanzini</surname><given-names>F</given-names></name><name><surname>Pizzetti</surname><given-names>F</given-names></name><etal>et al</etal><article-title>PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans</article-title><source>Circulation</source><year>2000</year><volume>102</volume><issue>6</issue><fpage>636</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.102.6.636</pub-id><pub-id pub-id-type="pmid">10931803</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Maugeri</surname><given-names>N</given-names></name><name><surname>Rovere-Querini</surname><given-names>P</given-names></name><name><surname>Slavich</surname><given-names>M</given-names></name><name><surname>Coppi</surname><given-names>G</given-names></name><name><surname>Doni</surname><given-names>A</given-names></name><name><surname>Bottazzi</surname><given-names>B</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><etal>et al</etal><article-title>Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction</article-title><source>J Immunol</source><year>2011</year><volume>187</volume><issue>2</issue><fpage>970</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1100261</pub-id><pub-id pub-id-type="pmid">21677138</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Helseth</surname><given-names>R</given-names></name><name><surname>Solheim</surname><given-names>S</given-names></name><name><surname>Opstad</surname><given-names>T</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Seljeflot</surname><given-names>I</given-names></name><article-title>The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention</article-title><source>Mediators Inflamm</source><year>2014</year><volume>2014</volume><fpage>608414</fpage><pub-id pub-id-type="doi">10.1155/2014/608414</pub-id><pub-id pub-id-type="pmid">24737925</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Nebuloni</surname><given-names>M</given-names></name><name><surname>Pasqualini</surname><given-names>F</given-names></name><name><surname>Zerbi</surname><given-names>P</given-names></name><name><surname>Lauri</surname><given-names>E</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Vago</surname><given-names>L</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><article-title>PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis</article-title><source>Cardiovasc Pathol</source><year>2011</year><volume>20</volume><issue>1</issue><fpage>e27</fpage><fpage>35</fpage><pub-id pub-id-type="doi">10.1016/j.carpath.2010.02.005</pub-id><pub-id pub-id-type="pmid">20356766</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Latini</surname><given-names>R</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Peri</surname><given-names>G</given-names></name><name><surname>Gonzini</surname><given-names>L</given-names></name><name><surname>Lucci</surname><given-names>D</given-names></name><name><surname>Mocarelli</surname><given-names>P</given-names></name><name><surname>Vago</surname><given-names>L</given-names></name><etal>et al</etal><article-title>Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>16</issue><fpage>2349</fpage><lpage>2354</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000145167.30987.2E</pub-id><pub-id pub-id-type="pmid">15477419</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Jeon</surname><given-names>HK</given-names></name><name><surname>You</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>MY</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Shim</surname><given-names>BJ</given-names></name><etal>et al</etal><article-title>Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome</article-title><source>Korean Circ J</source><year>2010</year><volume>40</volume><issue>8</issue><fpage>370</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.4070/kcj.2010.40.8.370</pub-id><pub-id pub-id-type="pmid">20830250</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Preda</surname><given-names>MB</given-names></name><name><surname>Ronningen</surname><given-names>T</given-names></name><name><surname>Burlacu</surname><given-names>A</given-names></name><name><surname>Simionescu</surname><given-names>M</given-names></name><name><surname>Moskaug</surname><given-names>JO</given-names></name><name><surname>Valen</surname><given-names>G</given-names></name><article-title>Remote transplantation of mesenchymal stem cells protects the heart against ischemia-reperfusion injury</article-title><source>Stem Cells</source><year>2014</year><volume>32</volume><issue>8</issue><fpage>2123</fpage><lpage>2134</lpage><pub-id pub-id-type="doi">10.1002/stem.1687</pub-id><pub-id pub-id-type="pmid">24578312</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Schindhelm</surname><given-names>RK</given-names></name><name><surname>van der Zwan</surname><given-names>LP</given-names></name><name><surname>Teerlink</surname><given-names>T</given-names></name><name><surname>Scheffer</surname><given-names>PG</given-names></name><article-title>Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?</article-title><source>Clin Chem</source><year>2009</year><volume>55</volume><issue>8</issue><fpage>1462</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2009.126029</pub-id><pub-id pub-id-type="pmid">19556446</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Hazen</surname><given-names>SL</given-names></name><article-title>Myeloperoxidase and cardiovascular disease</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2005</year><volume>25</volume><issue>6</issue><fpage>1102</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000163262.83456.6d</pub-id><pub-id pub-id-type="pmid">15790935</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Goldmann</surname><given-names>BU</given-names></name><name><surname>Rudolph</surname><given-names>V</given-names></name><name><surname>Rudolph</surname><given-names>TK</given-names></name><name><surname>Holle</surname><given-names>AK</given-names></name><name><surname>Hillebrandt</surname><given-names>M</given-names></name><name><surname>Meinertz</surname><given-names>T</given-names></name><name><surname>Baldus</surname><given-names>S</given-names></name><article-title>Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction</article-title><source>Free Radic Biol Med</source><year>2009</year><volume>47</volume><issue>1</issue><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.04.004</pub-id><pub-id pub-id-type="pmid">19362143</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Yilmaz</surname><given-names>S</given-names></name><name><surname>Inandiklioglu</surname><given-names>N</given-names></name><name><surname>Yildizdas</surname><given-names>D</given-names></name><name><surname>Subasi</surname><given-names>C</given-names></name><name><surname>Acikalin</surname><given-names>A</given-names></name><name><surname>Kuyucu</surname><given-names>Y</given-names></name><name><surname>Bayram</surname><given-names>I</given-names></name><etal>et al</etal><article-title>Mesenchymal stem cell: does it work in an experimental model with acute respiratory distress syndrome?</article-title><source>Stem Cell Rev</source><year>2013</year><volume>9</volume><issue>1</issue><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s12015-012-9395-2</pub-id><pub-id pub-id-type="pmid">22810359</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Danchuk</surname><given-names>SD</given-names></name><name><surname>Imhof</surname><given-names>KM</given-names></name><name><surname>Semon</surname><given-names>JA</given-names></name><name><surname>Scruggs</surname><given-names>BA</given-names></name><name><surname>Bonvillain</surname><given-names>RW</given-names></name><name><surname>Strong</surname><given-names>AL</given-names></name><etal>et al</etal><article-title>Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injury</article-title><source>Stem Cell Res Ther</source><year>2013</year><volume>4</volume><issue>1</issue><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/scrt161</pub-id><pub-id pub-id-type="pmid">23360775</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name><article-title>Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats</article-title><source>J Inflamm (Lond)</source><year>2012</year><volume>9</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1476-9255-9-33</pub-id><pub-id pub-id-type="pmid">22974286</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Song</surname><given-names>EC</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Sinn</surname><given-names>DI</given-names></name><etal>et al</etal><article-title>Systemic transplantation of human adipose stem cells attenuated cerebral inflammation and degeneration in a hemorrhagic stroke model</article-title><source>Brain Res</source><year>2007</year><volume>1183</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2007.09.005</pub-id><pub-id pub-id-type="pmid">17920570</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Lunde</surname><given-names>K</given-names></name><name><surname>Solheim</surname><given-names>S</given-names></name><name><surname>Aakhus</surname><given-names>S</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Abdelnoor</surname><given-names>M</given-names></name><name><surname>Forfang</surname><given-names>K</given-names></name><article-title>Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects</article-title><source>Scand Cardiovasc J</source><year>2005</year><volume>39</volume><issue>3</issue><fpage>150</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1080/14017430510009131</pub-id><pub-id pub-id-type="pmid">16152682</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><name><surname>Lunde</surname><given-names>K</given-names></name><name><surname>Solheim</surname><given-names>S</given-names></name><name><surname>Aakhus</surname><given-names>S</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Abdelnoor</surname><given-names>M</given-names></name><name><surname>Egeland</surname><given-names>T</given-names></name><name><surname>Endresen</surname><given-names>K</given-names></name><etal>et al</etal><article-title>Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><issue>12</issue><fpage>1199</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa055706</pub-id><pub-id pub-id-type="pmid">16990383</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><name><surname>Grajek</surname><given-names>S</given-names></name><name><surname>Popiel</surname><given-names>M</given-names></name><name><surname>Gil</surname><given-names>L</given-names></name><name><surname>Breborowicz</surname><given-names>P</given-names></name><name><surname>Lesiak</surname><given-names>M</given-names></name><name><surname>Czepczynski</surname><given-names>R</given-names></name><name><surname>Sawinski</surname><given-names>K</given-names></name><etal>et al</etal><article-title>Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: Impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>6</issue><fpage>691</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp536</pub-id><pub-id pub-id-type="pmid">20022872</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Wojakowski</surname><given-names>W</given-names></name><name><surname>Ruzyllo</surname><given-names>W</given-names></name><name><surname>Chojnowska</surname><given-names>L</given-names></name><name><surname>Kepka</surname><given-names>C</given-names></name><name><surname>Tracz</surname><given-names>W</given-names></name><name><surname>Musialek</surname><given-names>P</given-names></name><etal>et al</etal><article-title>Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><issue>11</issue><fpage>1313</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp073</pub-id><pub-id pub-id-type="pmid">19208649</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><name><surname>Traverse</surname><given-names>JH</given-names></name><name><surname>McKenna</surname><given-names>DH</given-names></name><name><surname>Harvey</surname><given-names>K</given-names></name><name><surname>Jorgenso</surname><given-names>BC</given-names></name><name><surname>Olson</surname><given-names>RE</given-names></name><name><surname>Bostrom</surname><given-names>N</given-names></name><name><surname>Kadidlo</surname><given-names>D</given-names></name><etal>et al</etal><article-title>Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction</article-title><source>Am Heart J</source><year>2010</year><volume>160</volume><issue>3</issue><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2010.06.009</pub-id><pub-id pub-id-type="pmid">20826249</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><name><surname>Wohrle</surname><given-names>J</given-names></name><name><surname>Merkle</surname><given-names>N</given-names></name><name><surname>Mailander</surname><given-names>V</given-names></name><name><surname>Nusser</surname><given-names>T</given-names></name><name><surname>Schauwecker</surname><given-names>P</given-names></name><name><surname>von Scheidt</surname><given-names>F</given-names></name><name><surname>Schwarz</surname><given-names>K</given-names></name><etal>et al</etal><article-title>Results of intracoronary stem cell therapy after acute myocardial infarction</article-title><source>Am J Cardiol</source><year>2010</year><volume>105</volume><issue>6</issue><fpage>804</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2009.10.060</pub-id><pub-id pub-id-type="pmid">20211323</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><name><surname>Maugeri</surname><given-names>N</given-names></name><name><surname>Rovere-Querini</surname><given-names>P</given-names></name><name><surname>Evangelista</surname><given-names>V</given-names></name><name><surname>Godino</surname><given-names>C</given-names></name><name><surname>Demetrio</surname><given-names>M</given-names></name><name><surname>Baldini</surname><given-names>M</given-names></name><name><surname>Figini</surname><given-names>F</given-names></name><etal>et al</etal><article-title>An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>6</issue><fpage>e39484</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0039484</pub-id><pub-id pub-id-type="pmid">22761804</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><name><surname>Sulpice</surname><given-names>T</given-names></name><name><surname>Boucher</surname><given-names>F</given-names></name><name><surname>Pucheu</surname><given-names>S</given-names></name><name><surname>de Leiris</surname><given-names>J</given-names></name><article-title>Contribution of leukocyte infiltration to lipoperoxidation occurring in the non-ischemic region of the rat heart submitted to permanent left coronary artery occlusion</article-title><source>J Mol Cell Cardiol</source><year>1994</year><volume>26</volume><issue>7</issue><fpage>831</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1006/jmcc.1994.1100</pub-id><pub-id pub-id-type="pmid">7966351</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Nallaratnam</surname><given-names>M</given-names></name><name><surname>Mocatta</surname><given-names>T</given-names></name><name><surname>Smyth</surname><given-names>D</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>JM</given-names></name><name><surname>Blake</surname><given-names>J</given-names></name><etal>et al</etal><article-title>Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction</article-title><source>Am J Cardiol</source><year>2010</year><volume>106</volume><issue>3</issue><fpage>316</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2010.03.028</pub-id><pub-id pub-id-type="pmid">20643239</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><name><surname>Eggers</surname><given-names>KM</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Johnston</surname><given-names>N</given-names></name><name><surname>Simoons</surname><given-names>ML</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>James</surname><given-names>SK</given-names></name><article-title>Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome</article-title><source>Clin Biochem</source><year>2013</year><volume>46</volume><issue>16-17</issue><fpage>1655</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2013.08.014</pub-id><pub-id pub-id-type="pmid">24012697</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><name><surname>Matsubara</surname><given-names>J</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name><name><surname>Konishi</surname><given-names>M</given-names></name><name><surname>Ohba</surname><given-names>K</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><etal>et al</etal><article-title>Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><issue>7</issue><fpage>861</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2010.10.018</pub-id><pub-id pub-id-type="pmid">21310324</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><name><surname>Hedstrom</surname><given-names>E</given-names></name><name><surname>Astrom-Olsson</surname><given-names>K</given-names></name><name><surname>Ohlin</surname><given-names>AK</given-names></name><name><surname>Ohlin</surname><given-names>H</given-names></name><name><surname>Arheden</surname><given-names>H</given-names></name><article-title>Initial results of inflammatory response, matrix remodeling, and reactive oxygen species following PCI in acute ischemic myocardial injury in man</article-title><source>J Invasive Cardiol</source><year>2011</year><volume>23</volume><issue>9</issue><fpage>371</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">21891809</pub-id></element-citation></ref></ref-list></back></article>